2021
Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib
Holowka T, Cheung H, Malinis M, Gan G, Deng Y, Perreault S, Isufi I, Azar MM. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib. Journal Of Infection And Chemotherapy 2021, 27: 1700-1705. PMID: 34389223, DOI: 10.1016/j.jiac.2021.08.005.Peer-Reviewed Original ResearchConceptsInvasive fungal infectionsSerious infectionsRisk factorsHematologic malignanciesAdvanced ageMultivariate analysis risk factorsSmall molecule tyrosine kinase inhibitorsSingle tertiary care centerFungal infectionsConcurrent useCytotoxic agentsMolecule tyrosine kinase inhibitorsAnalysis risk factorsTertiary care centerTyrosine kinase inhibitorsElectronic medical recordsResult of infectionMost patientsClinical featuresInfected patientsMedical recordsCare centerImmune effectorsPatientsViral infection
2018
Prescribing and dispensing practices for medicines used to treat non-communicable diseases in Uganda: a cross-sectional study
Ngongoni R, Gan G, Deng Y, Agaba G, Akiteng A, Schwartz J. Prescribing and dispensing practices for medicines used to treat non-communicable diseases in Uganda: a cross-sectional study. The Lancet Global Health 2018, 6: s23. DOI: 10.1016/s2214-109x(18)30152-9.Peer-Reviewed Original ResearchNon-communicable diseasesHealth care facilitiesPublic health care facilitiesCross-sectional studyNCD medicinesBackground Non-communicable diseasesNational essential medicines listsPre-tested structured questionnaireEssential Medicines ListNCD clinicsCare cascadeMost patientsHeart failureMiddle-income countriesPrimary outcomeChronic conditionsPrescribed dosesCardiovascular diseaseWHO methodologyDiabetes medicinesMedicines ListPatientsAverage ageDispensing practicesTotal doses